Hemophilia B Market
Oct 27, 2023
AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure
Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
